FDA accepts to review AbbVie’s sNDA for ibrutinib in cGVHD

This article was originally published here

The US Food and Drug Administration (FDA) has accepted for review AbbVie’s supplemental new drug application (sNDA) for ibrutinib (Imbruvica) in chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply